Anti-PD1 treatment has recently become standard of care in the adjuvant setting for patients with resected stage III (pembrolizumab or nivolumab) or stage IV melanoma with no evidence of disease (nivolumab) [10,11]. Here, PDCD1 is linked to melanoma.